CIA
CRL icon

Concurrent Investment Advisors’s Charles River Laboratories CRL Stock Holding History

Concurrent Investment Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$351K Sell
1,548
-12
-0.8% -$2.14K ﹤0.01% 1604
2026
Q1 		$269K Buy
1,560
+221
+17% +$41K ﹤0.01% 1570
2025
Q4 		$267K Buy
+1,339
New +$243K ﹤0.01% 1473
2025
Q2 		– Sell
-1,412
Closed -$213K – 1420
2025
Q1 		$213K Buy
+1,412
New +$237K 0.01% 1102

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Concurrent Investment Advisors's CRL Position: Q2 2026 in Review

Concurrent Investment Advisors reduced its Charles River Laboratories (CRL) stake by 0.77% in Q2 2026, selling an estimated $2.14K and leaving 1,548 shares worth $351K. The position accounts for ﹤0.01% of the portfolio, ranked #1604.

Concurrent Investment Advisors first reported a position in CRL in Q1 2025 and has held it in 4 quarters since. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Concurrent Investment Advisors held 1,548 shares of Charles River Laboratories worth $351K as of Q2 2026.
  • Concurrent Investment Advisors sold 12 Charles River Laboratories shares in Q2 2026, an estimated $2.14K.
  • Charles River Laboratories made up ﹤0.01% of Concurrent Investment Advisors's portfolio in Q2 2026, its #1604 holding.
  • Concurrent Investment Advisors first reported a position in Charles River Laboratories in Q1 2025 and has held it in 4 quarters since.
  • 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.